Vector Bioscience Cambridge has been selected to join the Future Medicines Accelerator, a programme delivered by LYVA Labs and funded by Innovate UK’s Biomedical Catalyst. The initiative supports UK SMEs developing the next generation of advanced therapeutics through tailored mentoring, expert-led modules, and commercialisation support.
Participation in this accelerator will connect Vector with programme partners, mentors, and fellow innovators working across the UK health and life sciences ecosystem. The program will also allow Vector to continue building on the technical and strategic progress achieved under our previous Innovate UK’s Biomedical Catalyst and Horizon Europe projects. And it will contribute to strengthen our pipeline and expand collaborations to advance our mission to develop safer, more effective drug delivery systems for hard-to-treat cancers.
